SEC Form 4 · accession 0001209191-19-004547

Deciphera Pharmaceuticals, Inc. · DCPH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Scientific Officer

Period of report

Mar 23, 2018

Accepted (ET)

Jan 18, 2019 · 4:13 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001654151

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Mar 23, 2018	G	91,779	$0.00	A	91,779	I	By Daniel L. Flynn Irrevocable Trust
Common Stock	Mar 23, 2018	G	91,779	$0.00	D	55,270	I	By Biochenomix, LLC
Common Stock	Jan 16, 2019	M	152,629	$1.89	A	152,629	D
Common Stock	Jan 16, 2019	S	152,629	$26.00	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F3	$1.89	Jan 16, 2019	M	152,629	D	—	Dec 17, 2025	Common Stock	152,629	472,678	D

F1This transaction involved a transfer of shares to the Daniel L. Flynn Irrevocable Trust from Biochenomix, LLC. The Reporting Person's daughter is trustee of the trust and the Reporting Person's spouse is the sole lifetime beneficiary of the trust. The Reporting Person disclaims Section 16 beneficial ownership over all such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that the Reporting Person has beneficial ownership of such shares for Section 16 or for any other purposes.
F2The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F3This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015.